Tarun Girotra1, Alain Lekoubou2, Kinfe G Bishu3, Bruce Ovbiagele4. 1. Department of Neurology, University of New Mexico, Albuquerque, NM, United States of America. Electronic address: tagirotra@salud.unm.edu. 2. Department of Neurology, Medical University of South Carolina, Charleston, SC, United States of America; Department of Neurology, University of New Mexico, Albuquerque, NM, United States of America. 3. Department of Medicine, Medical University of South Carolina, Charleston, SC, United States of America; Charleston Health Equity and Rural Outreach Innovation Center (HEROIC), Ralph H. Johnson VA Medical Center, Charleston, SC, United States of America. 4. Department of Neurology, University of California San Francisco, San Francisco, CA, United States of America.
Abstract
BACKGROUND: While several studies have determined direct costs associated with stroke there is a paucity of research involving indirect costs, especially in younger patients. AIM: Perform a cost of illness analysis for ischemic and non-traumatic hemorrhagic stroke in the US involving both direct and indirect costs in all age groups. METHODS: Nationally representative data was obtained from the Medical Expenditure Panel Survey (2003-2014). Subjects were dichotomized based on reported history of stroke. Two-part econometric models were used to estimate the adjusted incremental direct expenditure for patients with stroke. We used generalized linear model with family gamma, log link for the adjusted analysis of annual wage, a negative binomial regression model for the adjusted analysis of missed-work day, and a logistic regression model to estimate the probability of full-year employment. Loss of productivity due to premature death was computed using Present-Value of one life and annual number of deaths from 2014 National Vital Statistics. All costs are represented in 2016 US-dollar values. RESULTS: Out of 253,235,052 participants, 8,101,159 (3.2%) reported history of stroke. Weighted samples of 10,155 stroke participants and 314,694 control group were compared. Adjusted annual direct costs for each stroke participant was $4317 (95% CI: $3828-$4807) greater than control resulting in a net $38 billion incremental expenditure. Based on salary difference, missed workdays, and mortality, indirect cost from under-employment was $38.1 billion and from premature mortality was $30.4 billion. CONCLUSION: Total aggregate of $103.5 billion expenditure was incurred with 66% being from indirect costs based on 2016 US-dollar values.
BACKGROUND: While several studies have determined direct costs associated with stroke there is a paucity of research involving indirect costs, especially in younger patients. AIM: Perform a cost of illness analysis for ischemic and non-traumatic hemorrhagic stroke in the US involving both direct and indirect costs in all age groups. METHODS: Nationally representative data was obtained from the Medical Expenditure Panel Survey (2003-2014). Subjects were dichotomized based on reported history of stroke. Two-part econometric models were used to estimate the adjusted incremental direct expenditure for patients with stroke. We used generalized linear model with family gamma, log link for the adjusted analysis of annual wage, a negative binomial regression model for the adjusted analysis of missed-work day, and a logistic regression model to estimate the probability of full-year employment. Loss of productivity due to premature death was computed using Present-Value of one life and annual number of deaths from 2014 National Vital Statistics. All costs are represented in 2016 US-dollar values. RESULTS: Out of 253,235,052 participants, 8,101,159 (3.2%) reported history of stroke. Weighted samples of 10,155 strokeparticipants and 314,694 control group were compared. Adjusted annual direct costs for each strokeparticipant was $4317 (95% CI: $3828-$4807) greater than control resulting in a net $38 billion incremental expenditure. Based on salary difference, missed workdays, and mortality, indirect cost from under-employment was $38.1 billion and from premature mortality was $30.4 billion. CONCLUSION: Total aggregate of $103.5 billion expenditure was incurred with 66% being from indirect costs based on 2016 US-dollar values.
Authors: Alain Lekoubou; Djibril M Ba; Clever Nguyen; Guodong Liu; Douglas L Leslie; Leonardo Bonilha; Chinchilli M Vernon Journal: Neurology Date: 2022-05-18 Impact factor: 11.800
Authors: Sydney E Sneed; Kelly M Scheulin; Erin E Kaiser; Madison M Fagan; Brian J Jurgielewicz; Elizabeth S Waters; Samantha E Spellicy; Kylee J Duberstein; Simon R Platt; Emily W Baker; Steven L Stice; Holly A Kinder; Franklin D West Journal: Front Neurol Date: 2021-01-21 Impact factor: 4.003
Authors: Stefan Strilciuc; Diana Alecsandra Grad; Constantin Radu; Diana Chira; Adina Stan; Marius Ungureanu; Adrian Gheorghe; Fior-Dafin Muresanu Journal: J Med Life Date: 2021 Sep-Oct
Authors: Thinni Nurul Rochmah; Indana Tri Rahmawati; Maznah Dahlui; Wasis Budiarto; Nabilah Bilqis Journal: Int J Environ Res Public Health Date: 2021-07-15 Impact factor: 3.390